Responsive Image

 

 

Responsive Image

Enfermedades digestivas

Líneas de investigación

Enfermedad inflamatoria intestinal (colitis ulcerosa y enfermedad de Crohn) y enfermedades relacionadas
Desarrollo de nuevas técnicas endoscópicas diagnósticas y terapéuticas para el diagnóstico de lesiones neoplásicas y preneoplásicas del tracto digestivo

Foto grupo

Actividades del grupo

Papel de la aféresis leucocitaria.

Características e historia natural de la enfermedad inflamatoria intestinal preclínica.

Enfermedad perianal. Eficacia de los tratamientos biológicos y papel de la resonancia magnética en su evaluación.

Eficacia de los fármacos biológicos en el tratamiento de las complicaciones de la enfermedad inflamatoria intestinal.

Coordinador/a del grupo



Miembros del grupo

  Jose Luis Cabriada Nuño
 
  Marta Aduna de Paz
 
 
  Juan Antonio Arévalo Serna
 
 
  Inmaculada Barredo Santamaría
 
 
  Ainara Elorza Echániz
 
 
  Alberto Fernández Atutxa
 
 
  Alain Huerta Madrigal
 
 
  Irene Moraleja Yudego
 
 
  Ainhoa Rodríguez Pescador
 
 
  Cristina San Juan López
 
 
  Daniel Oyón Lara
 
 

Publicaciones del grupo

Sanz B, Rezola Pardo C, Arrieta H, Fernandez Atutxa A, Lora Diaz I, Gil Goikouria J, et al. High serum angiotensin-converting enzyme 2 activity as a biomarker of frailty in nursing home residents. Exp Gerontol. 2022; 158. DOI:10.1016/j.exger.2021.111655.

Gutierrez Moreno G, Ruiz Litago F, Ariz U, Fernandez Atutxa A, Mulas Martin MJ, Benito Fernandez E, et al. Successful breastfeeding among women with intention to breastfeed: From physiology to socio-cultural factors. Early Hum Dev. 2022; 164. DOI:10.1016/j.earlhumdev.2021.105518.

Barreiro de Acosta M, Riestra S, Calafat M, Soto MP, Calvo M, Sanchez Rodriguez E, et al. Management and long-term outcomes of Crohn's disease complicated with enterocutaneous fistula: ECUFIT study from GETECCU. J Crohns Colitis. 2022; 16(7): 1049-1058. DOI:10.1093/ecco-jcc/jjac016.

Zabana Y, Marin Jimenez I, Rodriguez Lago I, Vera I, Martin Arranz MD, Guerra I, et al. Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry. J Clin Med. 2022; 11(2). DOI:10.3390/jcm11020421.

Gutierrez A, Zapater P, Ricart E, Gonzalez Vivo M, Gordillo J, Olivares D, et al. Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients. Front Med. 2022; 9: 823900-823900. DOI:10.3389/fmed.2022.823900.

Rodriguez Lago I, Hollenbach M, Archibugi L, Ciocan D, Libanio D, Nuzzo A, et al. Young GI angle: Challenges and opportunities as a trainee editor: The United European Gastroenterology journal experience. United European Gastroenterol J. 2022; 10(3): 348-353. DOI:10.1002/ueg2.12222.

Ramirez Castro C, Fiallegas Cano M, Rodriguez Lopez P, Cabriada Nuno JL. Liver abscess due to parvimonas micra. Rev Esp Enferm Dig. 2022. DOI:10.17235/reed.2022.8751/2022.

Molina Infante J, Rodriguez Lago I. Modifying the natural history of gastrointestinal diseases in Europe as a result of early diagnosis: From eosinophilic esophagitis to inflammatory bowel disease. United European Gastroenterol J. 2022; 10(7): 612-613. DOI:10.1002/ueg2.12256.

Elorza A, Arzallus T, Izagirre A, Vicuna M, Rodriguez C, Cabriada JL, et al. Efficacy and safety of mesenchymal stem cell therapy with darvadstrocel for complex perianal fistulizing Crohn's disease: multicentric experience in the Basque Country and Navarre. J Crohns Colitis. 2022; 16: 388-388

Cardona AM, Horta D, Florez Diez P, Vela M, Mesonero F, Belinchon CR, et al. Evaluation of the safety and effectiveness of direct-acting antiviral drugs in the treatment of hepatitis C in patients with inflammatory bowel disease: National multicenter study (ENEIDA registry). MIC project. J Crohns Colitis. 2022; 16: 321-322

Iglesias RF, Silva MSP, Marin S, Casanova MJ, Manosa M, Gonzalez Munoza C, et al. Therapeutic requirements in patients with Ulcerative Proctitis. Is it necessary immunosuppressive therapy in these patients?. J Crohns Colitis. 2022; 16: 322-323

Rodriguez Lago I, Aguirre U, de la Piscina PR, Munagorri A, Zapata E, Higuera R, et al. Subclinical inflammatory bowel disease precedes the diagnosis and leads to an increase on healthcare resources utilization: multicentric case-control study in the Basque Country. J Crohns Colitis. 2022; 16: 226-227

Rey IB, Suarez CC, Luque AM, Caballol B, Soutullo C, Bravo A, et al. Safety of Inflammatory Bowel Disease treatments in patients with Solid Organ Transplantation (EITOS study of GETECCU). J Crohns Colitis. 2022; 16: 361-362

Rey IB, Suarez CC, Luque AM, Caballol B, Soutullo C, Bravo A, et al. Inflammatory Bowel Disease (IBD) and Solid Organ Transplantation. Natural history of pre-existing and de novo IBD patients. (EITOS study of GETECCU). J Crohns Colitis. 2022; 16: 54-56

Baldan Martin M, Azkargorta M, Iloro I, Moreno LO, Garcia LA, Fernandez IS, et al. Proteomic profile of serum and urine in newly diagnosed patients with Inflammatory Bowel Disease: new approach for biomarker discovery. J Crohns Colitis. 2022; 16: 145-145

Chaparro M, Donday MG, Rubio S, Nunez A, Suarez CC, Madero L, et al. Management of immunomodulators and biologic agents in pregnant patients with inflammatory bowel: results from the DUMBO registry of GETECCU. J Crohns Colitis. 2022; 16: 496-498

Guijarro LG, Cano Martínez D, Toledo Lobo MV, Ruiz Llorente L, Chaparro M, Guerra I, et al. Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn's Disease Severity. Biomedicines. 2022; 10(3). DOI:10.3390/biomedicines10030727.

Munoza CG, Calafat M, Gisbert JP, Iglesias E, Minguez M, Sicilia B, et al. Clinical outcomes in familial versus sporadic inflammatory bowel disease diagnosed in the era of biological therapies. Prospective data from the ENEIDA registry. J Crohns Colitis. 2022; 16: 567-567

Ramirez Castro C, Jimenez Iragorri I, Martin Vicente N, Cabriada Nuno JL. Haemoperitoneum due to rupture of intra-abdominal varices. Rev Esp Enferm Dig. 2022. DOI:10.17235/reed.2022.8937/2022.

Riestra S, Taxonera C, Zabana Y, Carpio D, Chaparro M, Barrio J, et al. Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU. J Clin Med. 2022; 11(13). DOI:10.3390/jcm11133915.

Rodriguez Lago I, Barreiro de Acosta M. Mild to moderate ulcerative colitis: Call me by my name. United European Gastroenterol J. 2022. DOI:10.1002/ueg2.12299.

Gros B, Rodriguez Lago I. Editorial: thiopurines in the multidrug era-time to rescue our memories over half a century of experience. Aliment Pharmacol Ther. 2022; 56(6): 1080-1081. DOI:10.1111/apt.17164.

De Galan C, Truyens M, Peeters H, Mesonero Gismero F, Elorza A, Torres P, et al. The impact of vedolizumab and ustekinumab on articular extra-intestinal manifestations in inflammatory bowel disease patients: a real-life multicentric cohort study. J Crohns Colitis. 2022. DOI:10.1093/ecco-jcc/jjac058.

Chaparro M, Garre A, Nunez Ortiz A, Diz Lois Palomares MT, Rodriguez C, Riestra S, et al. Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study. J. Clin. Med. 2021, 10, 2885. J Clin Med. 2022; 11(19). DOI:10.3390/jcm11195816.

Ruiz IL, Arostegi HA, Atucha AF. Battery life of cardiac implantable electronic devices explanted in funeral homes: a potential resource for underserved nations. Expert Rev Med Devices. 2022; 19(9): 733-737. DOI:10.1080/17434440.2022.2130757.

Blasco V, Pinto FM, Fernandez Atucha A, Dodd NP, Fernandez Sanchez M, Candenas L. Female Infertility Is Associated with an Altered Expression Profile of Different Members of the Tachykinin Family in Human Granulosa Cells. Reprod Sci. 2022. DOI:10.1007/s43032-022-00998-9.

Algaba A, Guerra I, Ricart E, Iglesias E, Mañosa M, Gisbert JP et al. Extraintestinal Manifestations in Patients with Inflammatory Bowel Disease: Study Based on the ENEIDA Registry. Dig Dis Sci. 2021; 66(6): 2014-2023. DOI:10.1007/s10620-020-06424-x.

Rodriguez Lago I, Alonso Galan H, Cabriada JL. Cytokine storm in IBD: balancing the risks of IBD medical therapy. Gastroenterology. 2021; 160(5): 1878-1880. DOI:10.1053/j.gastro.2020.12.073.

Bermejo F, Jimenez L, Algaba A, Vela M, Bastida G, Merino O et al. Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy. Inflamm Bowel Dis. 2021; 28(1): 41-47. DOI:10.1093/ibd/izab015.

Gutierrez A, Rodriguez Lago I. How to Optimize Treatment With Ustekinumab in Inflammatory Bowel Disease: Lessons Learned From Clinical Trials and Real-World Data. Front Med (Lausanne). 2021; 8: 640813-640813. DOI:10.3389/fmed.2021.640813.

Calvo XC, Carpio D, Rodriguez Lago I, Garcia Vicuna R, Acosta MB, Roura XJ et al. Risk of infection associated with Janus Kinase (JAK) inhibitors and biological therapies in inflammatory intestinal disease and rheumatoid arthritis. Prevention strategies. Gastroenterol Hepatol. 2021; 44(8): 587-598. DOI:10.1016/j.gastrohep.2021.01.007.

Torres J, Halfvarson J, Rodriguez Lago I, Hedin CRH, Jess T, Dubinsky M et al. Results of the Seventh Scientific Workshop of ECCO: Precision medicine in IBD- prediction and prevention of inflammatory bowel disease. J Crohns Colitis. 2021; 15(9): 1443-1454. DOI:10.1093/ecco-jcc/jjab048.

Barreiro de Acosta M, Marin Jimenez I, Rodriguez Lago I, Guarner F, Espin E, Bradley IF et al. Recommendations of the Spanish Working Group on Crohn's disease and ulcerative colitis (GETECCU) on pouchitis in ulcerative colitis. Part 2: Treatment (vol 43, pg 649, 2020). Gastroenterol Hepatol. 2021; 44(4): 320-320. DOI:10.1016/j.gastrohep.2021.02.001.

Rodriguez Lago I, Barreiro de Acosta M. Risk of Depression During the Natural History of Inflammatory Bowel Disease: The Phantom Menace. Inflamm Bowel Dis. 2021; 27(9): 99-100. DOI:10.1093/ibd/izab067.

Rodriguez Lago I, Agirre U, Intxaurza N, Cantero D, Cabriada JL, Barreiro de Acosta M. Increased use of healthcare resources during the preclinical period of inflammatory bowel disease. Dig Liver Dis. 2021; 53(7): 927-930. DOI:10.1016/j.dld.2021.04.002.

Sebastian delaCruz M, Olazagoitia Garmendia A, Madrigal AH, Garcia Etxebarria K, Mendoza LM, Fernandez Jimenez N et al. A Novel Noninvasive Method Based on Salivary Inflammatory Biomarkers for the Screening of Celiac Disease. Cell Mol Gastroenterol Hepatol. 2021; 12(4). DOI:10.1016/j.jcmgh.2021.05.016.

Magro F, Nuzzo A, Abreu C, Libanio D, Rodriguez Lago I, Pawlak K et al. COVID-19 in gastroenterology: Where are we now? Current evidence on the impact of COVID-19 in gastroenterology. United European Gastroenterol J. 2021; 9(7): 750-765. DOI:10.1002/ueg2.12115.

Chaparro M, Garre A, Nunez Ortiz A, Diz Lois Palomares MT, Rodriguez C, Riestra S et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study. J Clin Med. 2021; 10(13). DOI:10.3390/jcm10132885.

Rodriguez Lago I, Barreiro de Acosta M. The natural history of extraintestinal manifestations after surgery in inflammatory bowel disease: Never give up!. United European Gastroenterol J. 2021; 9(7): 748-749. DOI:10.1002/ueg2.12127.

Sainz E, Zabana Y, Miguel I, Fernandez Clotet A, Beltran B, Nunez L et al. Clinical features, therapeutic requirements and evolution of patients with Crohn's disease and upper gastrointestinal involvement (CROHNEX study). Aliment Pharmacol Ther. 2021; 54(8): 1041-1051. DOI:10.1111/apt.16547.

Ferreiro Iglesias R, Hernandez Camba A, Serrano Labajos R, Rodriguez Lago I, Zabana Y, Barreiro de Acosta M et al. SARS-CoV-2 vaccine acceptance among gastroenterologists and inflammatory bowel disease patients: VACUNEII project. Gastroenterol Hepatol. 2021. DOI:10.1016/j.gastrohep.2021.08.004.

Rodriguez Lago I, Mesonero F, Hijos Mallada G, Canas M, Saldana R, Savini C et al. Self-medication with analgesics reported by patients with ulcerative colitis: An anonymous survey. Gastroenterol Hepatol. 2021; 45(6): 457-463. DOI:10.1016/j.gastrohep.2021.07.009.

Guijarro LG, Cano Martínez D, Toledo Lobo MV, Salinas PS, Chaparro M, Gómez Lahoz AM et al. Relationship between IGF-1 and body weight in inflammatory bowel diseases: Cellular and molecular mechanisms involved. Biomed Pharmacother. 2021; 144: 112239-112239. DOI:10.1016/j.biopha.2021.112239.

Bermejo F, Jimenez L, Algaba A, Vela M, Bastida G, Merino O et al. Corrigendum to: Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy. Inflamm Bowel Dis. 2021; 28(1): 150-150. DOI:10.1093/ibd/izab242.

Pico S, Parras A, Santos Galindo M, Pose Utrilla J, Castro M, Fraga E et al. CPEB alteration and aberrant transcriptome-polyadenylation lead to a treatable SLC19A3 deficiency in Huntington's disease. Sci Transl Med. 2021; 13(613). DOI:10.1126/scitranslmed.abe7104.

Stephens C, Robles Diaz M, Medina Caliz I, Garcia Cortes M, Ortega Alonso A, Sanabria Cabrera J et al. Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry. J Hepatol. 2021; 75(1): 86-97. DOI:10.1016/j.jhep.2021.01.029.

Hernandez Camba A, Arranz L, Vera I, Carpio D, Calafat M, Lucendo AJ et al. Real-world use of mycophenolate mofetil in inflammatory bowel disease: Results from the ENEIDA registry. Dig Liver Dis. 2021; 54(5): 635-641. DOI:10.1016/j.dld.2021.10.002.

Rodriguez Lago I, Perez CG, Calafat M, Soto MP, Calvo M, Rodriguez ES et al. Long-term outcomes of enterocutaneous fistula complicating Crohn's Disease: The ECUFIT study from GETECCU. J Crohns Colitis. 2021; 15: 70-71. DOI:10.1093/ecco-jcc/jjab073.071.

Rodriguez Lago I, Agirre U, Intxaurza N, Cantero D, Barreiro de Acosta M, Cabriada JL. Healthcare resources utilisation prior to the diagnosis of ulcerative colitis and Crohn's disease. J Crohns Colitis. 2021; 15: 270-270. DOI:10.1093/ecco-jcc/jjab076.336.

Eek A, Protopapas AA, Pisani A, Barberio B, Frias Gomes C, Noviello D et al. VARIATION IN IBD CARE AND EDUCATION ACROSS EUROPE RESULTS FROM A PAN-EUROPEAN SURVEY. Gut. 2021; 70: 30-30. DOI:10.1136/gutjnl-2021-BSG.53.

Iglesias RF, Camba AH, Saldana R, Rodriguez Lago I, Zabana Y, Barreiro de Acosta M et al. Adherence to vaccination recommendations in patients with Inflammatory Bowel Disease: a long way for improving. J Crohns Colitis. 2021; 15: 410-411. DOI:10.1093/ecco-jcc/jjab076.527.

Abdo YZ, Marin Jimenez I, Rodriguez Lago I, Vera I, Martin MD, Guerra I et al. Comorbidities and epidemiological risk factor but not immunosuppressive therapies increase the risk of COVID-19 in Inflammatory Bowel Disease (IBD): An ENEIDA-based, case-control study. J Crohns Colitis. 2021; 15: 78-79. DOI:10.1093/ecco-jcc/jjab073.079.

Deza DC, Calvo LJL, Mainar J, Ricart E, Gisbert JP, Tirado MR et al. Effectiveness and safety of ustekinumab in elderly patients: Real world evidence from ENEIDA registry. J Crohns Colitis. 2021; 15: 298-299. DOI:10.1093/ecco-jcc/jjab076.388.

Abdo YZ, Marin Jimenez I, Rodriguez Lago I, Estesos ER, Meijilde S, Ramos L et al. Inflammatory Bowel Disease (IBD) and immunosuppression do not worsen the prognosis of COVID-19. Results from the ENEIDA Project of GETECCU. J Crohns Colitis. 2021; 15: 553-554. DOI:10.1093/ecco-jcc/jjab076.729.

Gisnsero FM, Zabana Y, Fernandez Cloret A, Sola A, Caballol B, Leo E et al. Inflammatory complications of the pouch, and therapetic requirements after colectomy in patients with ulcerative colitis. Results from the RESERVO Study of GETECCU. J Crohns Colitis. 2021; 15: 198-199. DOI:10.1093/ecco-jcc/jjab076.232.

Kral J, Nakov R, Lanska V, Barberio B, Benech N, Blesl A et al. Large differences in IBD care and education across Europe, first results of the pan-European VIPER survey. J Crohns Colitis. 2021; 15: 75-76. DOI:10.1093/ecco-jcc/jjab073.076.

Rodriguez Lago I, Fernandez Clotet A, Mesonero F, Garcia Alonso FJ, Casanova MJ, Fernandez de la Varga M et al. Long-term outcomes of biologic therapy in Crohn's disease complicated with internal fistulizing disease: BIOSCOPE study from GETECCU. J Crohns Colitis. 2021; 15: 377-378. DOI:10.1093/ecco-jcc/jjab076.481.

Chaparro M, Donday MG, Suarez CC, Rubio S, Figueira M, Martinez IP et al. Safety of Inflammatory Bowel Disease drugs during pregnancy and breastfeeding: Mothers and babies' outcomes (DUMBO registry). J Crohns Colitis. 2021; 15: 86-88. DOI:10.1093/ecco-jcc/jjab073.091.

Chaparro M, Garre A, Ortiz AN, Palomares MTDL, Rodriguez C, Riestra S et al. Risk and predictors of surgery in a newly diagnosed cohort of IBD patients in the biologic era: Results from the EpidemIBD study. J Crohns Colitis. 2021; 15: 18-20. DOI:10.1093/ecco-jcc/jjab075.019.

Ciria MM, Calafat M, Ricart E, Nos P, Iglesias E, Riestra S et al. Management and outcome of postoperative Crohn's Disease in the elderly as compared to young adults: Data from Eneida registry. J Crohns Colitis. 2021; 15: 69-70. DOI:10.1093/ecco-jcc/jjab073.070.

Arechederra M, Rullan M, Amat I, Oyon D, Zabalza L, Elizalde M et al. Next-generation sequencing of bile cell-free DNA for the early detection of patients with malignant biliary strictures. Gut. 2021. DOI:10.1136/gutjnl-2021-325178.

Oyon Lara D, Fernandez Atucha A, Lopez M, Cabriada Nuno JL. Polycystic pancreas, gastrointestinal manifestation of von Hippel-Lindau disease. Gastroenterol Hepatol. 2021; 45: 73-74. DOI:10.1016/j.gastrohep.2021.11.011.

Sanz B, Arrieta H, Rezola Pardo C, Fernandez Atutxa A, Garin Balerdi J, Arizaga N et al. Low serum klotho concentration is associated with worse cognition, psychological components of frailty, dependence, and falls in nursing home residents. Sci Rep. 2021; 11(1). DOI:10.1038/s41598-021-88455-6.

Albéniz E, Gimeno García AZ, Fraile M, Ibáñez B, Guarner Argente C, Alonso Aguirre P, et al. Clinical validation of risk-scoring systems to predict risk of delayed bleeding after endoscopic mucosal resection of large colorectal lesions. Gastrointest Endosc. 2020; 91(4): 868-8783. DOI:10.1016/j.gie.2019.10.013.

Rodríguez Lago I, Gisbert JP. The role of immunomodulators and biologics in the medical management of stricturing Crohn's disease. J Crohns Colitis. 2020; 14(4): 557-566. DOI:10.1093/ecco-jcc/jjz158.

Rivero Sánchez L, Arnau Collell C, Herrero J, Remedios D, Alvarez V, Albéniz E, et al. White-light Endoscopy is Adequate for Lynch Syndrome Surveillance in a Randomized and Non-inferiority Study. Gastroenterology. 2020; 158(4): 895-9041. DOI:10.1053/j.gastro.2019.09.003.

Fiallegas Cano M, Moraleja Yudego I, Sampedro Andrada B, de Castro Santos L, Jiménez Iragorri I, Martín Vicente N, et al. Giant sigmoid diverticulum. Gastroenterol Hepatol. 2020; 43(1): 30-31. DOI:10.1016/j.gastrohep.2019.07.008.

Chaparro M, Guerra I, Iborra M, Cabriada JL, Bujanda L, Taxonera C, et al. Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease. Eur J Gastroenterol Hepatol. 2020; 32(5): 588-596. DOI:10.1097/MEG.0000000000001706.

Rodriguez Lago I, Castro Poceiro J, Fernandez Clotet A, Mesonero F, Lopez Sanroman A, Lopez Garcia A, et al. Tacrolimus induces short-term but not long-term clinical response in inflammatory bowel disease. Aliment Pharmacol Ther. 2020; 51(9): 870-879. DOI:10.1111/apt.15687.

Canas M, Mesonero F, Rodriguez Lago I, Savini C, Saldana R, Feo Luca L, et al. Factors related to self-medication with corticosteroids, aminosalicylates or analgesics and reasons given by patients with ulcerative colitis from Spain. J Crohns Colitis. 2020; 14: 657-657

Colomino M, Beltran B, Fernandez Clotet A, Flores EI, Navarro P, Rivero M, et al. Real-world long-term effectiveness of ustekinumab in Crohn's disease: Results from the ENEIDA registry. J Crohns Colitis. 2020; 14: 458-460

Gismero FM, Rodriguez Lago I, Canas M, Claudia S, Saldana R, Feo Lucas L, et al. Self-Medication with steroids in ulcerative colitis: Results of a patient survey. J Crohns Colitis. 2020; 14: 480-481

Rodriguez Lago I, Del Hoyo J, Casanova MJ, Fernandez Clotet A, Garcia MJ, Ferreiro Iglesias R, et al. Long-term effectiveness of anti-TNF agents in symptomatic stricturing Crohn's disease. J Crohns Colitis. 2020; 14: 467-468

Rodroguez Lago I, Gismeno FM, Canas M, Savini C, Saldana R, Feo Lucas L, et al. Self-medication with analgesics in ulcerative colitis: Results of a patient survey. J Crohns Colitis. 2020; 14: 349-350

Rodriguez Lago I, Merino O, Azagra I, Maiz A, Zapata E, Higuera R, et al. Risk of progression of preclinical ulcerative colitis. J Crohns Colitis. 2020; 14: 238-239

Abdo YZ, de Francisco R, Rodriguez Lago I, Chaparro M, Gomollon F, Piqueras M, et al. Low adhesion to latent tuberculosis (TB) screening recommendations in inflammatory bowel disease (IBD) patients: Results of the INFEII registry of GETECCU. J Crohns Colitis. 2020; 14: 614-615

Heinrich H, Rodr?guez Lago I, Nakov R, Skuja V, Acedo P, Nitsche U, et al. Young GI Societies in Europe: 2019 update. United European Gastroenterol J. 2020; 8(2): 227-232. DOI:10.1177/2050640620906771.

Skuja V, Nakov R, van Herwaarden Y, Rodriguez Lago I, Acedo P, Mikolasevic I, et al. How to start a Young GI Section in your country: A cookbook. United European Gastroenterol J. 2020; 8(3): 355-358. DOI:10.1177/2050640620912635.

Macaluso FS, Rodriguez Lago I. JAK inhibition as a therapeutic strategy for inflammatory bowel disease. Curr Drug Metab. 2020; 21(4): 247-255. DOI:10.2174/1389200221666200310111409.

Rodriguez Lago I, Ramirez de la Piscina P, Elorza A, Merino O, Ortiz de Zarate J, Cabriada JL. Characteristics and prognosis of patients with inflammatory bowel disease during the SARS-CoV-2 pandemic in the Basque Country (Spain). Gastroenterology. 2020; 159(2): 781-783. DOI:10.1053/j.gastro.2020.04.043.

Ramos Lopez L, Hernandez Camba A, Rodriguez Lago I, Carrillo Palau M, Cejas Dorta L, Elorza A, et al. Usefulness of magnetic resonance enterography in the clinical decision-making process for patients with inflammatory bowel disease. Gastroenterol Hepatol. 2020; 43(8): 439-445. DOI:10.1016/j.gastrohep.2020.03.007.

Martínez AL, Calles Romero LA, Etxeberría Martín E, Monasterio Jiménez O, Zabalegui Eguinoa A, Paja Fano M, et al. ¿Hay vida después de teduglutida?. Nutr Hosp. 2020; 34(3): 631-635. DOI:10.20960/nh.03052.

Chaparro M, Barreiro de Acosta M, Benitez JM, Cabriada JL, Casanova MJ, Ceballos D, et al. Epidemiology, clinical characteristics, evolution and treatments in newly diagnosed inflammatory bowel disease (IBD): Results from the nationwide EpidemIBD study of GETECCU. J Crohns Colitis. 2020; 14: 594-597

Iborra M, Beltran B, Fernandez Clotet A, Flores EI, Cortes PN, Rivero M, et al. REAL-WORLD LONG-TERM EFFECTIVENESS OF USTEKINUMAB IN CROHN'S DISEASE: RESULTS FROM THE ENEIDA REGISTRY. Gastroenterology. 2020; 158(6): 953-953

Camba AH, Hernandez LA, Vera I, Carpio D, Calafat M, Lucendo A, et al. USE OF MYCOPHENOLATE MOFETIL IN INFLAMMATORY BOWEL DISEASE: RESULTS FROM ENEIDA REGISTRY. Gastroenterology. 2020; 158(6): 1213-1213

Martin Vicente N, Rodriguez Lago I, Barredo Santamaria I, Cabriada JL. Apoptotic colitis owing to dolutegravir. Gastroenterol Hepatol. 2020; 43(10): 638-639. DOI:10.1016/j.gastrohep.2020.01.018.

Marin Jimenez I, Zabana Y, Rodriguez Lago I, Marin L, Acosta MB, Esteve M, et al. [COVID-19 and inflammatory bowel disease: questions arising from patient care and follow-up during the initial phase of the pandemic (February-April 2020)]. Gastroenterol Hepatol. 2020; 43(7): 408-413. DOI:10.1016/j.gastrohep.2020.05.003.

Rodriguez Lago I, Ramirez C, Merino O, Azagra I, Maiz A, Zapata E, et al. Early microscopic findings in preclinical inflammatory bowel disease. Dig Liver Dis. 2020; 52(12): 1467-1472. DOI:10.1016/j.dld.2020.05.052.

Barreiro de Acosta M, Marin Jimenez I, Rodriguez Lago I, Guarner F, Espin E, Ferrer Bradley I, et al. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 2: Treatment. Gastroenterol Hepatol. 2020; 43(10): 649-658. DOI:10.1016/j.gastrohep.2020.04.004.

Elorza A, Rodríguez Lago I, Martínez P, Hidalgo A, Aguirre U, Cabriada JL. Gastrointestinal infection with Aeromonas: incidence and relationship to inflammatory bowel disease. Gastroenterol Hepatol. 2020; 43(10): 614-619. DOI:10.1016/j.gastrohep.2020.04.014.

Rodriguez Lago I, Hoyo JD, Perez Girbes A, Garrido Marin A, Casanova MJ, Chaparro M, et al. Early treatment with anti-tumor necrosis factor agents improves long-term effectiveness in symptomatic stricturing Crohn's disease. United European Gastroenterol J. 2020; 8(9): 1056-1066. DOI:10.1177/2050640620947579.

Rodriguez Lago I, Zabana Y, Barreiro de Acosta M. Diagnosis and natural history of preclinical and early inflammatory bowel disease. Ann Gastroenterol. 2020; 33(5): 443-452. DOI:10.20524/aog.2020.0508.

Rodriguez Lago I, Marigorta UM, Acosta MB. Preclinical inflammatory bowel disease: back to the future. Gastroenterology. 2020; 160(1): 475-476. DOI:10.1053/j.gastro.2020.04.081.

Mesonero F, Julia B, Saldana R, Savini C, Canas M, Cea Calvo L, et al. Self-medication with oral corticosteroids reported by patients with ulcerative colitis: characteristics, reasons and patients' behaviors. Eur J Gastroenterol Hepatol. 2020; 33(4): 501-507. DOI:10.1097/MEG.0000000000001931.

Canete F, Manosa M, Perez Martinez I, Barreiro de Acosta M, Gonzalez Sueyro RC, Nos P, et al. Antitumor Necrosis Factor Agents to Treat Endoscopic Postoperative Recurrence of Crohn's Disease: A Nationwide Study With Propensity-Matched Score Analysis. Clin Transl Gastroenterol. 2020; 11(8): 218-218. DOI:10.14309/ctg.0000000000000218.

Rodriguez Lago I, Barreiro de Acosta M. Look at Both Sides of the Coin in Determining Risk of Complicated Crohn's Disease. Clin Gastroenterol Hepatol. 2021; 19(7): 1503-1504. DOI:10.1016/j.cgh.2020.07.027.

Caldas M, Perez Aisa A, Castro Fernandez M, Bujanda L, Lucendo AJ, Rodrigo L, et al. European Registry on Helicobacter pylori Management: Effectiveness of First and Second-Line Treatment in Spain. Antibiotics-Basel. 2020; 10(1). DOI:10.3390/antibiotics10010013.

Carretero Ribon C, Prieto Frias C, Angos R, Betes M, Herraiz Bayod M, de la Riva Onandia S, et al. Pan-enteric capsule for bleeding high-risk patients. Can we limit endoscopies?. Rev Esp Enferm Dig. 2020; 113(8): 580-584. DOI:10.17235/reed.2020.7196/2020.

Rivero Sanchez L, Gavric A, Herrero J, Remedios D, Alvarez V, Albeniz E, et al. The "diagnose and leave in" strategy for diminutive rectosigmoid polyps in Lynch syndrome: a post hoc analysis from a randomized controlled trial. Endoscopy. 2020. DOI:10.1055/a-1328-5405.

Balsa A, Lojo Oliveira L, Alperi López M, García Manrique M, Ordóñez Cañizares C, Pérez L, et al. Prevalence of Comorbidities in Rheumatoid Arthritis and Evaluation of Their Monitoring in Clinical Practice: The Spanish Cohort of the COMORA Study. Reumatol Clin. 2019; 15(2): 102-108. DOI:10.1016/j.reuma.2017.06.002.

Chavarría C, Casanova MJ, Chaparro M, Barreiro de Acosta M, Ezquiaga E, Bujanda L, et al. Prevalence and Factors Associated with Fatigue in Patients with Inflammatory Bowel Disease: A Multicenter Study. J Crohns Colitis. 2019; 13(8): 996-1002. DOI:10.1093/ecco-jcc/jjz024.

Chaparro M, Garre A, Ricart E, Iglesias Flores E, Taxonera C, Domenech E, et al. Differences between childhood- and adulthood-onset inflammatory bowel disease: the CAROUSEL study from GETECCU. Aliment Pharmacol Ther. 2019; 49(4): 419-428. DOI:10.1111/apt.15114.

Chaparro M, Aterido A, Guerra I, Iborra M, Cabriada J, Bujanda L, et al. Functional rare variants influence the clinical response to anti-TNF therapy in Crohn's disease. J Crohns Colitis. 2019; 13(1): 530-531

Casanova MJ, Chaparro M, Minguez M, Ricart E, Taxonera C, Garcia Lopez S, et al. Effectiveness and safety of the sequential use of a second and third anti-TNF agent in patients with inflammatory bowel disease: results from the ENEIDA registry. J Crohns Colitis. 2019; 13(1): 329-330. DOI:10.1093/ecco-jcc/jjy222.563.

Calafat M, Manosa M, Panes J, Nos P, Iglesias E, Vera I, et al. Risk of immunomediated adverse events or secondary loss of response to infliximab in elderly patients with inflammatory bowel disease: a cohort study of the ENEIDA registry. J Crohns Colitis. 2019; 13(1): 328-329. DOI:10.1093/ecco-jcc/jjy222.561.

Sainz Arnau E, Zabana Y, Miguel I, Fernandez Clotet A, Casanova MJ, Martin MD, et al. Clinical features, therapeutic requirements, and evolution of patients with Crohn's disease and upper digestive tract involvement (CROHNEX study). J Crohns Colitis. 2019; 13(1): 332-332

Iborra M, Beltran B, Fernandez A, Gutierrez A, Antolin B, Huguet JM, et al. Real-world short-term effectiveness of ustekinumab in Crohn's disease: Results from the ENEIDA Registry. J Crohns Colitis. 2019; 13(1): 364-366. DOI:10.1093/ecco-jcc/jjy222.629.

Guerra I, Bujanda L, Castro J, Merino O, Tosca J, Camps B, et al. Clinical characteristics, associated malignancies and management of primary sclerosing cholangitis in inflammatory bowel disease patients: A multicenter retrospective cohort study. J Crohns Colitis. 2019; 13(12): 1492-1500. DOI:10.1093/ecco-jcc/jjz094.

Rodríguez Lago I, Barreiro de Acosta M. Short Disease Duration Does Not Always Indicate Early Crohn's Disease. Clin Gastroenterol Hepatol. 2019; 17(8): 1646-1646. DOI:10.1016/j.cgh.2019.01.017.

Andújar X, Loras C, González B, Socarras M, Sanchiz V, Boscà M, et al. Efficacy and safety of endoscopic balloon dilation in inflammatory bowel disease: results of the large multicenter study of the ENEIDA registry. Surg Endosc. 2019; 34(3): 1112-1122. DOI:10.1007/s00464-019-06858-z.

Carmona Abellan M, Rodriguez Lago I, Luis Cabriada J, Carlos Gomez Esteban J. The relationship between inflammatory bowel disease and Parkinson's disease: true or fiction?. Scand J Gastroenterol. 2019; 54(7): 886-889. DOI:10.1080/00365521.2019.1641739.

Barreiro De Acosta M, Domenech E, Martin Arranz MD, Garcia Sanchez V, Gutierrez Casbas A, Chaparro M, et al. Endoscopic follow-up and therapeutic attitude after ileocolonic resection in a nationwide Spanish cohort of Crohn's disease patients: the Practicrohn study. Expert Rev Gastroenterol Hepatol. 2019; 13(8): 807-813. DOI:10.1080/17474124.2019.1626717.

Rodriguez Lago I, Ferreiro Iglesias R, Nos P, Gisbert JP, G. Management of acute severe ulcerative colitis in Spain: A nationwide clinical practice survey. Gastroenterol Hepatol. 2019; 42(2): 90-101. DOI:10.1016/j.gastrohep.2018.09.002.

Chaparro M, Barreiro de Acosta M, Benitez J, Cabriada J, Casanova M, Ceballos D, et al. Epidemiology, clinical characteristics, evolution and treatments in newly diagnosed inflammatory bowel disease (IBD): results from the nationwide EpidemIBD study of GETECCU. J Crohns Colitis. 2019; 13(1): 516-517. DOI:10.1093/ecco-jcc/jjy222.914.

Rodriguez Lago I, Castro Poceiro J, Fernandez Clotet A, Mesonero F, Lopez Sanroman A, Lopez Garcia A, et al. Efficacy and safety of tacrolimus in Crohn's disease: a nationwide, multi-centric study from GETECCU. J Crohns Colitis. 2019; 13(1): 207-208. DOI:10.1093/ecco-jcc/jjy222.347.

Rodriguez Lago I, Castro Poceiro J, Fernandez Clotet A, Mesonero F, Lopez Sanroman A, Lopez Garcia A, et al. Efficacy and safety of tacrolimus in ulcerative colitis: a nationwide, multi-centre study from GETECCU. J Crohns Colitis. 2019; 13(1): 52-53. DOI:10.1093/ecco-jcc/jjy222.078.

Chaparro M, Barreiro de Acosta M, Echarri A, Almendros R, Barrio J, Llao J, et al. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients. Dig Dis Sci. 2019; 64(3): 846-854. DOI:10.1007/s10620-018-5362-3.

Acedo P, Heinrich H, van Herwaarden Y, Nakov R, Nitsche U, Rodriguez Lago I, et al. UEG Young Talent Group: What do we do?. United European Gastroenterol J. 2019; 7(1): 166-168. DOI:10.1177/2397847319826451.

de Miguel E, Joven Ibanez B, Galindez E, Urrego Laurin C, Luz Garcia Vivar M, Fernandez Carballido C, et al. THE VALUE OF SACROILIAC JOINT RADIOGRAPHS IN THE EARLY SPONDYLOARTHRITIS ESPERANZA COHORT. Ann Rheum Dis. 2019; 78(2): 472-472. DOI:10.1136/annrheumdis-2019-eular.7696.

Tornero C, Urrego Laurin C, Luz Garcia Vivar M, Fernandez Carballido C, Juanola Roura X, Garcia Llorente JF, et al. RELIABILITY OF SACROILIAC JOINT RADIOGRAPHS IN THE EARLY SPONDYLOARTHRITIS ESPERANZA COHORT. Ann Rheum Dis. 2019; 78(2): 1821-1821. DOI:10.1136/annrheumdis-2019-eular.7768.

Irati U, Chinchilla Gallo PS, Hernandez Gomez S, Garcia Llorente JF, Aizpurua Manso I, Vegas Revenga N. DENSITOMETRY VALUES CHANGE WHEN STOPPING DENOSUMAB. Ann Rheum Dis. 2019; 78(2): 1896-1896. DOI:10.1136/annrheumdis-2019-eular.4338.

Canete F, Manosa M, Lobaton T, Mesonero F, Rodriguez Lago I, Cabre E, et al. Nivolumab-induced immune-mediated colitis: an ulcerative colitis look-alikereport of new cases and review of the literature. Int J Colorectal Dis. 2019; 34(5): 861-865. DOI:10.1007/s00384-019-03268-4.

Rodriguez Lago I, Sempere L, Gutierrez A, Nunez A, Leo Carnerero E, Hinojosa E, et al. Granulocyte-monocyte apheresis: an alternative combination therapy after loss of response to anti-TNF agents in ulcerative colitis. Scand J Gastroenterol. 2019; 54(4): 459-464. DOI:10.1080/00365521.2019.1600715.

Rodríguez Lago I, Merino O, López de Goicoechea MJ, Aranzamendi M, Zubiaurre L, Muro N, et al. Immunosuppression for inflammatory bowel disease does not influence Epstein-Barr viral load in the short-term. Gastroenterol Hepatol. 2019; 42(9): 542-547. DOI:10.1016/j.gastrohep.2019.03.016.

Calafat M, Manosa M, Canete F, Ricart E, Iglesias E, Calvo M, et al. Increased risk of thiopurine-related adverse events in elderly patients with IBD. Aliment Pharmacol Ther. 2019; 50(7): 780-788. DOI:10.1111/apt.15458.

Casanova MJ, Chaparro M, Mínguez M, Ricart E, Taxonera C, García López S, et al. Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry. Inflamm Bowel Dis. 2019; 26(4): 606-616. DOI:10.1093/ibd/izz192.

Domenech E, Panes J, Hinojosa J, Annese V, Magro F, Sturniolo GC, et al. Addition of Granulocyte/Monocyte Apheresis to Oral Prednisone for Steroid-dependent Ulcerative Colitis: A Randomized Multicentre Clinical Trial (vol 12, pg 687, 2018). J Crohns Colitis. 2019; 13(6): 814-814. DOI:10.1093/ecco-jcc/jjy211.

Chaparro M, Barreiro de Acosta M, Manuel Benitez J, Cabriada JL, Jose Casanova M, Ceballos D, et al. EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain. Ther Adv Gastroenterol. 2019; 12. DOI:10.1177/1756284819847034.

Rodriguez Lago I, Benitez JM, Sempere L, Saez Gonzalez E, Barreiro de Acosta M, de Zarate JO, et al. The combination of granulocyte-monocyte apheresis and vedolizumab: A new treatment option for ulcerative colitis?. J Clin Apheresis. 2019; 34(6): 680-685. DOI:10.1002/jca.21746.

Chaparro M, Aterido A, Guerra I, Iborra M, Cabriada JL, Bujanda L, et al. Functional rare variants influence the clinical response to anti-TNF therapy in Crohn's disease. Ther Adv Gastroenterol. 2019; 12. DOI:10.1177/1756284819867848.

Barreiro de Acosta M, Gutierrez A, Rodriguez Lago I, Espin E, Ferrer Bradley I, Marin Jimenez I, et al. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 1: Epidemiology, diagnosis and prognosis. Gastroenterol Hepatol. 2019; 42(9): 568-578. DOI:10.1016/j.gastrohep.2019.08.001.

Sanchez C, Hernani MT, Alvarez Calatayud G, Miranda Cid C, Manuel Navas V, Marin Jimenez I, et al. Status of transition care in inflammatory bowel disease in Spain. Different medical perspectives. Rev Esp Enferm Dig. 2019; 111(11): 833-838. DOI:10.17235/reed.2019.6310/2019.

Tesis del grupo

Autor/a: Iago Rodríguez Lago. Título: "Enfermedad inflamatoria intestinal preclínica: características de la enfermedad, pronóstico y necesidades de tratamiento". Directores/as: Dr. Miguel Muñoz Navas, Dr. Manuel Barreiro de Acosta.

© 2022 IIS Biocruces Bizkaia